Completed PHASE3 INTERVENTIONAL 2-arm NCT06329674

Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

Evaluate the Efficacy and Safety of the Combination of A51R3 and AJU-A51 Compared With the Combination of A51R3 and A51R2 in Patients With Type 2 Diabetes Mellitus

Sponsor: AJU Pharm Co., Ltd.

Conditions Type2 Diabetes

Interventions A51R2 A51R2 Placebo A51R3 AJU-A51 AJU-A51 Placebo

Updated 4 times since 2024 Last updated: Mar 25, 2024 Started: Apr 27, 2021 Primary completion: Dec 1, 2022 Completion: Jun 13, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type2 Diabetes, this trial is completed. The trial is conducted by AJU Pharm Co., Ltd. and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE3

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AJU Pharm Co., Ltd.

Data source: AJU Pharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea